Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05299749

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Boston VA Healthcare System, Brockton

Brockton, Massachusetts, 02301, United States

Location status: Recruiting

Location contact

Mia Kriksciun, BA

CONTACT

[email protected]

774 826 1507

About this study

Here, the investigators propose that neurofeedback aimed to regulate the superior temporal gyrus (STG) activation will not only lead to activation changes in the STG, but also to changes in the default mode network (DMN), as well as to reductions in AH, and that the brain and clinical changes will be correlated. The theoretical framework for the current proposal is an AH model that assumes that AH result from abnormalities in a network of regions including STG, and medial prefrontal cortex (MPFC) and posterior cingulate cortex (PCC), the two latter regions are core medial hubs of DMN that are related to self-referential processing. This model is supported by several theoretical papers and experimental evidence well as preliminary data by the investigators (PD). In both R61 and R33 the investigators will study SZ patients with medication resistant AH in the rt-fMRI intervention arm and in the sham-rt-fMRI arm. In both arms, the task and the rt-fMRI session structure will be identical. The SZ-intervention group will receive feedback from the STG while SZ-sham group will receive feedback from the motor cortex. In addition, 2 functional fMRI tasks will examine the effect of rt-fMRI neurofeedback and of sham-rt-fMRI on brain response. This R33 phase will consist of an SZ-intervention group (random n=52) that will receive 5 sessions of rt-fMRI feedback targeting STG, while SZ-sham group (random n=52) will receive 5 sham-rt-fMRI sessions. Based on our R61 phase data, the investigators predict that rt-fMRI feedback aimed at STG will reduce AH which will be, in turn, associated with reductions in the STG activation and in the DMN connectivity (i.e., brain changes achieved in R61 and replicated in R33) in SZ- intervention group only. Five sessions of rt-fMRI feedback will address the question of dose response at brain and clinical levels. The impact of rt-fMRI neurofeedback and of sham-rt-fMRI on AH (primary outcome), and on delusions, negative symptoms and working memory (WM) (exploratory outcome) will be assessed with clinical and neuropsychological measures. In an exploratory aim, based on the existing literature, the investigators predict the improvement in delusions, negative symptoms and in WM score, only post-rt-fMRI neurofeedback targeting the STG and not post-sham-rt-fMRI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria
  • auditory hallucinations not responsive to pharmacology as determined by chart review and a clinical interview of SCID.

Exclusion criteria

  • neurologic illness
  • major head trauma
  • electroconvulsive therapy
  • alcohol or drug dependence
  • alcohol or drug abuse within the past five years
  • verbal IQ below 70

Treatment and study plan

stg-rt-fMRI-Neurofeeback

Other

the patients will receive real-time feedback from the brain activity of the superior temporal gyrus

sham-rt-fMRI-Neurofeedback

Other

the patients will receive real-time feedback from the brain activity of the somato-motor cortex

Primary outcomes

  1. percent change in the STG BOLD signal, post- relative to pre-NFB

    Time frame: 0-4 weeks post intervention

    does real-time fMRI neurofidback reduce BOLD activity in STG, post NFB

Secondary outcomes

  1. reduction in scores on Psychotic Symptoms Rating Scale, post- relative to pre, NFB

    Time frame: 0-4 weeks post intervention

    does real-time fMRI neurofidback reduce auditory hallucinations, post NFB

  2. percent change in the MPFC-PCC connectivity measure, post- relative to pre-NFB.

    Time frame: 0-4 weeks post intervention

    Does real time NFB reduce connectivity in MPFC-PCC, post NFB

Study contacts

Contact information is provided by the study sponsor or research team.

Clemens Bauer, phd

CONTACT

[email protected]

617-870-1771

margaret niznikiewicz, PhD

CONTACT

[email protected]

6176534627

Sponsors and collaborators

Lead sponsor

Boston VA Research Institute, Inc.

Other

Collaborators

  • Cambridge Health Alliance
  • Mclean Hospital
  • Northeastern University

Registry information

Official study title

Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients With Schizophrenia - R33 Phase

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 29, 2022
Registry last updated
Sep 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.